Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $176.77 Consensus Target Price from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have earned a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $176.77.

Several research analysts have recently commented on the stock. Needham & Company LLC restated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research note on Monday, January 27th. HC Wainwright reaffirmed a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 13th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Guggenheim upped their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Sarepta Therapeutics in a research note on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price objective on the stock.

Insider Transactions at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Sarepta Therapeutics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock valued at $1,104,701,000 after buying an additional 117,904 shares in the last quarter. Capital International Investors grew its holdings in Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock worth $1,057,482,000 after acquiring an additional 2,437,855 shares during the last quarter. Janus Henderson Group PLC increased its position in Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Farallon Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 11.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock worth $348,368,000 after acquiring an additional 285,100 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 0.7 %

Shares of Sarepta Therapeutics stock opened at $105.56 on Thursday. The stock has a 50-day simple moving average of $117.11 and a 200-day simple moving average of $123.14. Sarepta Therapeutics has a 52-week low of $101.15 and a 52-week high of $173.25. The firm has a market cap of $10.08 billion, a price-to-earnings ratio of 84.45 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.